TL;DR — Butyrate is the short-chain fatty acid your own colonic bacteria make when you eat fermentable fiber — it's the primary fuel for colonocytes and a genuine HDAC inhibitor. Oral supplementation (microencapsulated sodium butyrate or tributyrin) has real human RCT support, but almost entirely in disease populations — IBS, diverticulosis, ulcerative colitis, type 2 diabetes — at doses of 300 mg to 1.5 g/day. The largest and most rigorous trial to date (n=181, MASLD) missed its primary liver-fat endpoint. No trial has tested it in healthy adults for a longevity outcome. Evidence tierTNiC's A/B/C grading of how strong the human research is behind a compound. Full glossary →: B, honestly disease-population evidence, not a settled healthy-adult intervention.
What butyrate does (and why the gut needs it)
Butyrate is a four-carbon short-chain fatty acid (SCFA) produced when colonic bacteria — largely Faecalibacterium prausnitzii, Roseburia, and other Firmicutes — ferment resistant starch and soluble fiber that survives digestion in the small intestine. Unlike acetate and propionate, which are mostly exported to the liver and periphery, butyrate is preferentially consumed locally: it supplies an estimated 60-70% of the ATP used by colonocytes, the cells lining the colon. That dual identity — local fuel source and signaling molecule — is why butyrate shows up in both metabolic and epigenetic research.
The reason it's sold as a supplement at all is that this SCFA doesn't just get burned for energy. Above the concentrations needed for fuel, it inhibits Class I and IIa histone deacetylases (HDACs), and it binds the SCFA receptors GPR41 (FFAR3) and GPR109A (HCAR2) on enteroendocrine cells, colonic macrophages, and Tregs. Oral products exist because fiber intake and gut microbial fermentation capacity are highly variable between individuals, and because uncoated butyric acid tastes and smells foul enough (rancid butter) that direct oral dosing requires microencapsulation or a prodrug form like tributyrin.
Primary hallmarks targeted: Dysbiosis · Epigenetic dysregulation · Chronic inflammation
The strongest dedicated human RCT is Krokowicz et al. 2014 (PMID 24343275, International Journal of Colorectal Disease): 73 diverticulosis patients randomized to microencapsulated sodium butyrate 300 mg/day vs placebo for 12 months; the butyrate group had significantly fewer diverticulitis episodes (6.7% vs 31.8% of controls, p=0.043). But the largest and most recent human RCT — Mitrović et al. 2025 (PMID 40565024, International Journal of Molecular Sciences), 181 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) given sodium or calcium butyrate 1,000 mg/day — found no significant change in the primary liver-fat endpoint (controlled attenuation parameter), with only selective subgroup metabolic improvements. Both are real trials; they simply point in different directions on different outcomes.
Mechanism: HDAC inhibition, GPR41/GPR109A, and the "butyrate paradox"
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| HDAC inhibition (Class I/IIa) | Hyperacetylates histone H3/H4, de-repressing anti-inflammatory and barrier-gene transcription | Epigenetic dysregulation |
| GPR109A (HCAR2) activation | Anti-inflammatory signaling in colonic macrophages and Tregs; the receptor tributyrin acts through in adipose tissue (Sato et al. 2020, PMID 32882837) | Chronic inflammation |
| GPR41 (FFAR3) activation | Enteroendocrine signaling linked to satiety hormones and glucose homeostasis | Dysbiosis |
| Colonocyte β-oxidation | Primary ATP substrate for the colonic epithelium — normal colonocytes burn it for fuel, while cancerous colonocytes (glycolytic, "Warburg" phenotype) accumulate it and are instead growth-arrested by its HDAC-inhibiting action | Dysbiosis |
This last row is what researchers call the "butyrate paradox": the same molecule promotes normal colonocyte proliferation as a fuel source but suppresses proliferation in glycolytic/cancerous colonocytes as an HDAC inhibitor, because the two cell types use it completely differently. It's a real, well-characterized cell-biology finding — worth knowing, but it describes colonic cell behavior in a dish and animal models, not a human longevity outcome.
Oral butyrate vs. fermentable fiber — these are not interchangeable levers
An oral SCFA capsule delivers a fixed, episodic dose of the end-product. Fermentable fiber (inulin, resistant starch, psyllium) instead feeds your existing colonic bacteria to produce butyrate continuously, at whatever level your microbiome composition and transit time allow, while also remodeling the microbiota itself. The trials behind oral butyrate are almost all in patients with a defined GI or metabolic diagnosis — there is no dedicated RCT testing whether supplementing a healthy adult with normal fiber intake produces any measurable benefit over what their fermentation already provides.
Evidence summary — real RCTs, disease populations, one large null result
| Study | Design | N | Duration | Key outcome | Tier |
|---|---|---|---|---|---|
| Krokowicz 2014 (PMID 24343275) | RCT, diverticulosis | 52 completers | 12 months | ↓diverticulitis episodes: 6.7% vs 31.8% controls (p=0.043) | B |
| Banasiewicz 2013 (PMID 22738315) | RCT, IBS (adjunct therapy) | 66 | 12 wk | ↓pain on defecation, improved urgency/bowel habit; overall pain-severity change not significant | B |
| Firoozi 2024 (PMID 39003477) | Double-blind RCT, active ulcerative colitis | 36 | 12 wk | ↓inflammatory markers, upregulated circadian-clock genes, improved sleep quality and QoL | B |
| Panufnik 2026 (PMID 41974937) | RCT, type 2 diabetes with GI symptoms | 52 | 12 wk | ↓abdominal pain/diarrhea/bloating; ↓HbA1c and HOMA-IR vs placebo | B |
| Mitrović 2025 (PMID 40565024) | RCT, MASLD | 181 | interventional trial | No significant change in primary liver-fat endpoint (CAP); selective subgroup metabolic improvements only | C (null primary) |
| Sato 2020 (PMID 32882837) | Animal mechanism, diet-induced obese mice | — | 6 wk | Tributyrin ↓weight gain, ↑insulin sensitivity via GPR109A-dependent adipose remodeling | C (preclinical) |
← Swipe for more columns →
Consensus: Tier B. What's real: repeated, independent human RCTs at trial-relevant doses (300 mg–1.5 g/day) showing benefit in diverticulosis recurrence, IBS symptom scores, ulcerative colitis inflammatory markers, and glycemic markers in type 2 diabetes. What tempers it: every positive trial is in a diagnosed GI or metabolic condition, sample sizes are small (36-73 patients), and the single largest, most recent trial found no effect on its primary endpoint. There is no completed RCT of oral butyrate in healthy, asymptomatic adults for any longevity-relevant outcome.
Where butyrate disappoints
- Every positive trial is in a diagnosed condition. The benefits are in diverticulosis, IBS, ulcerative colitis, and type-2 diabetes — there's no evidence a healthy adult with normal fiber intake gains anything. - The biggest trial was null. The largest, most recent RCT (MASLD, n=181) missed its primary liver-fat endpoint — a real "this may do nothing" result, not a compliance failure. - A capsule isn't fiber. Oral butyrate delivers an episodic end-product and skips the microbial fermentation and community-remodeling that fiber-driven butyrate provides — often the better lever.
Does oral butyrate fit your protocol?
Is your primary goal a diagnosed GI condition (IBS, diverticulosis, active IBD) under physician care?
Butyrate has real RCT support as an adjunct in exactly these conditions — discuss microencapsulated dosing with your GI physician rather than self-starting alongside prescribed therapy
node | Is your goal general "gut health" or metabolic support with no diagnosed condition?
The evidence for healthy/asymptomatic adults is thin — prioritize fermentable fiber (inulin, resistant starch) as the better-supported route to raising endogenous colonic butyrate before adding an oral SCFA product
Treat it as an experimental Tier-B addition tracked against one specific marker (hs-CRP, stool pattern, or HbA1c if pre-diabetic), not a default longevity supplement
Active IBD flare with any risk of obstruction or perforation, or new/unexplained GI bleeding — get physician clearance before adding any SCFA supplement
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol & form selection
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 300 mg–1.5 g/day microencapsulated sodium butyrate, or 200–400 mg/day tributyrin | Krokowicz 2014 used 300 mg/day; Panufnik 2026 and Firoozi 2024 used 1.5 g/day and 600 mg/day respectively |
| Form | Microencapsulated / enteric-coated sodium butyrate for colonic-release, or tributyrin as a lipophilic prodrug | Uncoated free butyric acid has poor palatability and is largely absorbed before reaching the colon |
| Timing | With meals, split AM/PM | Reduces GI upset; matches trial dosing schedules |
| Duration before reassessing | 12 weeks for symptom/marker endpoints; 12 months for diverticulitis-recurrence-type endpoints | Matches the two trial designs above |
Week-one compliance checklist
- [ ] Confirm the label specifies microencapsulated/enteric-coated delivery (or a tributyrin prodrug) — not plain free-acid sodium butyrate
- [ ] Record baseline symptom or marker (hs-CRP, stool pattern, or HbA1c) before the first dose
- [ ] Take with meals, split into two doses if using the higher end of the trial range
- [ ] If you have any GI diagnosis, confirm dosing with your treating physician rather than layering it onto existing therapy unsupervised
Monitoring: hs-CRP, stool pattern, glycemic markers
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| hs-CRP | Trending down | Baseline, 12 wk | No change → reassess whether inflammation is actually the rate-limiting driver for you |
| Stool consistency/frequency (Bristol scale) | Improved regularity | Daily log, review at 4 and 12 wk | Worsening → reduce dose or switch form; discontinue if symptoms persist |
| HbA1c / fasting glucose (if metabolic goal) | Trending down | Baseline, 12 wk | Flat → butyrate likely isn't your primary lever; reassess fiber intake and other metabolic tools |
| GI tolerance | Manageable | Daily | Persistent bloating/gas → reduce dose or switch to a different delivery form |
← Swipe for more columns →
hs-CRP or inflammatory markers
Elevated
GI symptom score (if applicable)
Elevated
HbA1c (if pre-diabetic/diabetic)
Above target
hs-CRP or inflammatory markers
Modest reduction (disease populations only)
GI symptom score (if applicable)
Reduced frequency/severity
HbA1c (if pre-diabetic/diabetic)
Modest reduction
Safety, IBD caution, and interactions
- Generally well tolerated at trial doses — the most consistently reported side effects are transient bloating and gas, especially with uncoated forms.
- Uncoated free butyric acid has a strong rancid-butter odor and taste — this is the practical reason microencapsulated and tributyrin forms exist, not a marketing preference.
Do not self-treat active IBD with this instead of prescribed therapy
- Active inflammatory bowel disease — the ulcerative colitis trial (Firoozi 2024) dosed butyrate as a physician-supervised adjunct to standard therapy, not a replacement; do not substitute it for prescribed IBD medication.
- No dedicated pregnancy/nursing safety data — avoid without physician guidance.
- Unclear interaction profile with immunosuppressants and biologics used in IBD — get physician sign-off before combining.
- Don't conflate "raising butyrate levels" with "fixing dysbiosis" — an oral SCFA capsule bypasses the microbial fermentation and community-remodeling effects that fiber-driven butyrate production provides.
What would change this grade. Butyrate is B, carried entirely by disease-population trials. A completed RCT in healthy adults showing a longevity-relevant benefit would broaden the grade; the disease evidence, however solid, won't move the general-use case. The null MASLD primary endpoint is a genuine caution against over-reading it.
Who should skip butyrate
- Healthy adults with decent fiber intake — feed your own bacteria with fermentable fiber first; an oral SCFA adds little proven value here. - Active IBD flare — never substitute it for prescribed therapy; use only as a physician-supervised adjunct. - Pregnancy/nursing, or anyone on IBD immunosuppressants/biologics — safety and interaction data are lacking; get sign-off.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Inulin | Fermentable prebiotic fiber that colonic bacteria convert into endogenous butyrate — pairing supplies continuous microbial substrate rather than relying solely on episodic oral dosing | Inulin module |
| Berberine | Both compounds intersect gut-microbiota composition and glycemic control; T2D trials for each independently report HbA1c/HOMA-IR improvement, so check for overlapping rather than fully additive benefit before stacking | Berberine module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Prescribed IBD therapy (as a substitute) | Replacing standard treatment with butyrate risks an uncontrolled flare | Use only as a supervised adjunct, never a replacement |
| Adequate fermentable-fiber intake | Overlapping route to the same end-product — the capsule may add little on top | Prioritize fiber; add oral butyrate only for a targeted, monitored reason |
| IBD immunosuppressants / biologics | Interaction profile is uncharacterized | Get physician sign-off before combining |
Personal results template
My Butyrate (Sodium / Tributyrin) results log
| Date | Week | Dose / form | hs-CRP | Stool pattern (Bristol) | HbA1c (if tracked) | GI tolerance (1–10) | Notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | — | Baseline |
| YYYY-MM-DD | 12 | 300 mg–1.5 g/day | — | — | — | — | Primary endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: hs-CRP, stool pattern, or HbA1c trending in the favorable direction with good GI tolerance. - No effect: No measurable change at 12 weeks with confirmed compliance — the null MASLD result suggests this is a real possible outcome, not a compliance failure. - Stop and reassess: Worsening GI symptoms, new bleeding, or any change while on IBD-directed medication without physician sign-off.
See the fiber-first alternative
Butyrate supplements skip the fermentation step; inulin feeds it. For most healthy adults without a diagnosed GI condition, start there and use oral butyrate as a targeted, monitored addition rather than a default.
Inulin moduleReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.